Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs SentinelOne Inc. Class A Common Stock (S) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs SentinelOne Inc. Class A Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while SentinelOne Inc. Class A Common Stock trades at $22.63 (market cap $8.36B). The key difference: Kymera Therapeutics Inc. Common Stock and SentinelOne Inc. Class A Common Stock are close in size by market cap, and Kymera Therapeutics Inc. Common Stock is more actively traded (779,107 versus 27,558,313). Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and SentinelOne Inc. Class A Common Stock for 6 Days on average.
| KYMR | S | |
|---|---|---|
Market Cap | $8.87B | $8.36B |
Volume | 779,107 | 27,558,313 |
Sector | Health | Technology |
52-Week High | $127.31 | $26.27 |
52-Week Low | $55.80 | $11.94 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $8.26B | $7.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SentinelOne (S) trades at $24.01, down 6.43% amid news of a $1.25 billion convertible notes offering. The stock shows bullish technical signals with strong moving average support, though oscillators remain neutral. Fundamentally, the company maintains robust revenue growth (21% YoY) and high gross margins (72.54%) but continues to report significant net losses (-$288M in 2025). Recent analyst recognition as a leader in endpoint security and expanding cloud capabilities provide positive business momentum.
Investment outlook balances strong growth potential against persistent profitability challenges. The convertible notes offering signals aggressive expansion but increases financial leverage. With 65% analyst buy ratings and a $23.42 consensus target, Wall Street remains optimistic about long-term cybersecurity demand, though investors face execution risk and competitive pressures in a capital-intensive growth phase.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About SentinelOne Inc. Class A Common Stock
SentinelOne provides an AI-powered cybersecurity platform for organizations. Its Singularity platform helps detect, prevent, and respond to threats across endpoints, cloud workloads, identities, and connected devices.
Read more on S →
